CTMX Stock - CytomX Therapeutics, Inc.
Unlock GoAI Insights for CTMX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M |
| Gross Profit | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $25.00M | $-6,484,000 | $-101,335,000 | $-116,042,000 | $-80,540,000 |
| Net Income | $31.87M | $-569,000 | $-99,317,000 | $-115,870,000 | $-64,819,999 |
| Net Margin | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% |
| EPS | $0.38 | $-0.01 | $-1.48 | $-1.26 | $-0.71 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 22nd 2025 | Cantor Fitzgerald | Initiation | Overweight | $6 |
| September 17th 2025 | Barclays | Resumed | Overweight | $3.5 |
| July 31st 2025 | Oppenheimer | Initiation | Outperform | $7 |
| May 15th 2025 | H.C. Wainwright | Upgrade | Buy | $5 |
| April 14th 2025 | Piper Sandler | Resumed | Overweight | $2.5← $3.25 |
| May 28th 2024 | Piper Sandler | Upgrade | Overweight | $3.5← $2.25 |
| May 9th 2024 | Wedbush | Upgrade | Outperform | $8 |
| May 6th 2024 | Jefferies | Upgrade | Buy | $8← $2.5 |
| April 22nd 2024 | JP Morgan | Upgrade | Neutral | - |
| November 14th 2022 | BMO Capital Markets | Downgrade | Market Perform | $2.6← $3 |
| July 7th 2022 | Mizuho | Downgrade | Neutral | $4← $16 |
| July 7th 2022 | Piper Sandler | Downgrade | Neutral | $1.5← $10 |
| July 7th 2022 | Jefferies | Downgrade | Hold | $2← $12 |
| July 7th 2022 | Wedbush | Downgrade | Neutral | $2← $6 |
| June 24th 2022 | BMO Capital Markets | Initiation | Outperform | $9 |
Earnings History & Surprises
CTMXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.04 | $-0.09 | -125.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.06 | $-0.00 | +98.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $0.18 | $0.27 | +50.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.23 | $0.22 | +195.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.17 | $0.07 | +141.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.08 | $0.17 | +312.5% | ✓ BEAT |
Q1 2024 | Mar 11, 2024 | $0.00 | $0.01 | +134.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.19 | $0.04 | +121.1% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.19 | $-0.02 | +89.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.16 | $-0.05 | +68.8% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.21 | $-0.42 | -100.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.36 | $-0.37 | -2.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.25 | $-0.40 | -60.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.30 | $-0.35 | -16.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.26 | $-0.30 | -15.4% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $10
📈 PositiveCytomX Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeCytomX Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeCytomX Therapeutics Q3 EPS $(0.09) Misses $(0.05) Estimate, Sales $5.963M Miss $11.625M Estimate
📉 NegativeCytomX Therapeutics To Present Initial Translational Data From Ongoing Phase 1 Study Of CX-801 In Patients With Advanced Melanoma At SITC Annual Meeting
➖ NeutralBarclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $6
📈 PositiveCantor Fitzgerald Initiates Coverage On CytomX Therapeutics with Overweight Rating, Announces Price Target of $6
📈 PositiveCytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering
📈 PositiveFrequently Asked Questions about CTMX
What is CTMX's current stock price?
What is the analyst price target for CTMX?
What sector is CytomX Therapeutics, Inc. in?
What is CTMX's market cap?
Does CTMX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CTMX for comparison